SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Reports of layoffs in India and the Philippines, with termination notices citing a scaled-down business assignment, have sparked concern that Innodata may have lost or reduced a major client project. Traders are divided between that revenue-risk interpretation and the view that the cuts reflect efficiency or a shift to contract workers, with the uncertainty weighing on shares ahead of Q3 results.

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and décor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

A recent rebound that held near breakout levels has prompted bullish swing-trade setups and call buying ahead of earnings. Traders are watching for follow-through, while some remain cautious about weak housing demand and interest-rate sensitivity.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Attention centers on ImmunityBios upcoming QUILT-2.005 Phase 3 topline readout of ANKTIVA plus BCG for first-line bladder cancer; the company has completed the database lock and says an sBLA filing is on track for Q4. Traders are largely optimistic about the potential label expansion, while also watching Q3 results and debating whether the clinical and commercial momentum will justify the bullish expectations.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is drawing attention after a sharp precious-metals selloff and a reported 52-week low, with traders citing Fed rate-hike expectations and possible forced liquidation as pressures. The community is split between calling gold a failed safe haven and viewing the decline as a buying opportunity, with some watching for support or a rebound.

World Liberty Financial (WLFI) is a cryptocurrency launched in 2025and operates on the Ethereum platform. World Liberty Financial has a current supply of 100,000,000,000 with 31,779,991,497 in circulation. The last known price of World Liberty Financial is 0.05007445 USD and is up 0.02 over the last 24 hours. It is currently trading on 491 active market(s) with $20,910,403.62 traded over the last 24 hours. More information can be found at https://www.worldlibertyfinancial.com/.

WorldFinancial

WLFI discussion centers on its prolonged weakness and concerns that Trump-family crypto monetization and potential token sales are weighing on sentiment. Bulls counter that a bank charter and USD1-related utility could support a rebound, though those catalysts are discussed largely as expectations, while skeptics see no near-term support.

ProShares Trust II - ProShares Ultra VIX Short-Term Futures ETF 1.5x Shares

ProShares Ultra VIX Short-Term Futures ETF

UVXY is drawing attention after a sharp gain alongside elevated volatility and unusually heavy call activity. Traders are split between treating the move as a hedge against market risk and expecting the volatility spike to fade, citing the funds tendency to decay over time.

NextDecade Corp. is a development company, which focuses on liquefied natural gas (LNG) export projects and associated pipelines. It develops and manages land-based and floating liquefied natural gas projects in the Gulf Coast with focus on the Rio Grande LNG. The company was founded by Kathleen Eishbrenner in 2010 and is headquartered in Houston, TX.

NextDecade Corporation

Traders are framing disruptions to Qatari and other Middle Eastern LNG supply, including shipping risks around the Strait of Hormuz, as a potential tailwind for U.S. exporters and future contracting leverage at NextDecades Rio Grande project. Skeptics note that NEXT has not yet begun production and remains exposed to construction, financing, and execution risks ahead of planned first LNG output in 2027.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

AXSM is drawing attention after a steep selloff as investors await Q3 results to gauge whether Auvelitys Alzheimers-agitation launch is translating into paid prescriptions and whether commercial spending is delaying profitability. Some traders believe sampling and long-term-care channels understate demand, while others point to sluggish visible prescription growth, managements silence and cash-burn concerns.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladocs Q3 update sparked a sharp rally as traders focused on stronger profitability and cash generation, while revenue remained under pressure and BetterHelp continued to weigh on the growth outlook. Bulls are debating whether the results mark a turnaround and could pressure short sellers; skeptics see unresolved growth and execution risks.

Mobileye Global, Inc. engages in the business of developing and deploying driver assistance systems and autonomous driving technologies and solutions. It operates under the Mobileye and Other segments. The company was founded by Amnon Shashua and Ziv Aviram in 1999 and is headquartered in Jerusalem, Israel.

Mobileye Global Inc - Ordinary Shares - Class A

MOBILEYE GLOBAL INC

Mobileyes quarterly results beat expectations and included a modest outlook increase, but the shares sold off sharply and reached a 52-week low. Traders disagree over whether the decline is excessive given the companys cash position and buyback, or justified by weak growth, reliance on an R&D grant, and concerns about competition and demand for higher-end driver-assistance systems.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Genprex to Present TUSC2 Research from Sponsored Collaboration with Meharry Medical College at the Gerontological Society of America 2026 Annual Scientific Meeting

Genprex to Present TUSC2 Research from Sponsored Collaboration with Meharry Medical College at the Gerontological Society of America 2026 Annual Scientific Meeting Genprex to Present TUSC2 Research from Sponsored Collaboration with Meharry Medical College at the Gerontological Society of America...

Genprex Highlights New Preclinical Data Identifying Role of TUSC2, the Gene Used in REQORSA, in Maintaining Cellular Function During Brain Aging

Genprex Highlights New Preclinical Data Identifying Role of TUSC2, the Gene Used in REQORSA, in Maintaining Cellular Function During Brain Aging Genprex Highlights New Preclinical Data Identifying Role of TUSC2, the Gene Used in REQORSA, in Maintaining Cellular Function During Brain AgingPR...

Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference PR Newswire AUSTIN, Texas, Sept. 8, 2026 Company Presentation to Highlight Lead Clinical Oncology Program and Preclinical Diabetes...

Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy

Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene...

Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies

Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies PR Newswire AUSTIN, Texas, Aug. 3, 2026 Collaboration Advances Biomarker-Driven Patient Selection and Precision...

Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer

Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent...

Genprex to Participate at BIO International Convention 2026

Genprex to Participate at BIO International Convention 2026 Genprex to Participate at BIO International Convention 2026 PR Newswire AUSTIN, Texas, June 17, 2026 The BIO International Convention Brings Together More Than 20,000 Biotech Industry Leaders From Around The WorldAUSTIN, Texas, June 17...

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa Gene Therapy Published at the 2026 ASCO Annual Meeting

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa Gene Therapy Published at the 2026 ASCO Annual Meeting Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa Gene Therapy Published at the 2026 ASCO Annual Meeting PR Newswire AUSTIN, Texas, May 26, 2026 Trop-2 H-scores...

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting Genprex Collaborators Present...

Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa Gene Therapy and PD-1 Antibodies to Treat Cancer

Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa Gene Therapy and PD-1 Antibodies to Treat Cancer Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa Gene Therapy and PD-1 Antibodies to Treat Cancer PR Newswire AUSTIN...

Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company product is REQORSA immunogen therapy drug for non-small cell lung cancer. Its other technologies include GPX-002 gene therapy for diabetes, and ONCOPREX nanoparticle delivery system. Genprex was founded by J. Rodney Varner on April 1, 2009 and is headquartered in Austin, TX.

Genprex Inc

Walt Disney, VSee Health, Genprex: Retail Most Bullish On These 3 Stocks Pre-Market

Equity

Bearish Sentiment

Walt Disney Co. (<a class="mention" data-mention="$DIS" data-symbol-id="DIS" href="https://stocktwits.com/symbol/DIS" target="_blank">$DIS</a>)<figure class="image"><a href="https://stocktwits.com/symbol/DIS"><img style="aspect-ratio:1314/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/DIS_sentiment_and_message_volume_Oct_21_2024_7dcf3c3bd2.png" alt="DIS sentiment and message volume Oct 21 2024.png" width="1314" height="318"></a><figcaption>DIS sentiment and message volume Oct 21 2024 as of 7 am ET | source: Stocktwits</figcaption></figure>Sentiment on Stocktwits for Walt Disney Co. turned ‘bullish’ (69/100) early Monday before the market opened, compared to a ‘bearish’ sentiment just a day earlier. Disney’s stock has risen nearly 3.5% over the past week. Recent news driving the stock includes Disney’s announcement to pilot a new fast-pass option for rides at its U.S. theme parks, with peak pricing as high as $449. Additionally, Piper Sandler initiated coverage with a ‘Neutral’ rating and a $95 price target. The analyst noted limited upside in the next few quarters due to moderation in Disney’s experiences segment, but remains optimistic about Disney’s broader assets and recent film successes.VSee Health Inc. (<a class="mention" data-mention="$VSEE" data-symbol-id="VSEE" href="https://stocktwits.com/symbol/VSEE" target="_blank">$VSEE</a>)<figure class="image"><a href="https://stocktwits.com/symbol/VSEE"><img style="aspect-ratio:1314/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/GNPX_sentiment_and_message_volume_Oct_21_2024_3a5b20d8d3.png" alt="GNPX sentiment and message volume Oct 21 2024.png" width="1314" height="318"></a><figcaption>VSEE sentiment and message volume Oct 21 2024 as of 7 am ET | source: Stocktwits</figcaption></figure>VSee Health scored an ‘extremely bullish’ (97/100) sentiment on Stocktwits pre-market Monday, following a nearly 36% stock gain over the past week. The surge was driven by the announcement of a telehealth initiative in collaboration with Kwajalein Atoll Local Government (KALGOV) and Kwajalein Atoll Sustainability Laboratory (KASL). The project leverages SpaceX’s Starlink technology and VSee’s telemedicine platform to provide virtual healthcare consultations aboard a boat ambulance, aimed at improving access for Marshallese veterans and residents of the Kwajalein Atoll.Genprex, Inc. (<a class="mention" data-mention="$GNPX" data-symbol-id="GNPX" href="https://stocktwits.com/symbol/GNPX" target="_blank">$GNPX</a>)<figure class="image"><a href="https://stocktwits.com/symbol/GNPX"><img style="aspect-ratio:1314/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/VSEE_sentiment_and_message_volume_Oct_21_2024_70aa2e5cb4.png" alt="VSEE sentiment and message volume Oct 21 2024.png" width="1314" height="318"></a><figcaption>GNPX sentiment and message volume Oct 21 2024 as of 7 am ET | source: Stocktwits</figcaption></figure>Gene therapy company Genprex saw its Stocktwits sentiment hit ‘extremely bullish’ pre-market Monday, after a week of impressive gains over 28%. The optimism followed the company’s announcement that it had advanced to the highest dose group in its Acclaim-3 small cell lung cancer trial for Reqorsa Gene Therapy with Tecentriq, after receiving approval from a safety review committee. &nbsp;

Disney’s fast-pass pilot, VSee Health’s telehealth initiative, and Genprex’s gene therapy trial progress are driving strong interest

Walt Disney Co

VSee Health Inc.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$2.24
Prev Close	$2.04
Open	$2.04
Dividend Yield	0.00%
50-Day Moving Average	$2.97
Beta	1.38
Avg. Volume	212,151.64
PE Ratio	-0.01

52-Week High	$138.60
52-Week Low	$1.71
Market Capitalization	$1.84M
EPS (Annual)	-$382.79
Price to Book	0.08
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

GNPX Fundamentals